Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.
Pacira BioSciences, Inc. (Nasdaq: PCRX) is a pioneering company dedicated to advancing non-opioid pain management and regenerative health solutions. Headquartered in Tampa, Florida, Pacira is committed to providing innovative treatments that minimize the reliance on opioids for pain relief, thereby redefining the role of opioids as a rescue therapy only.
Pacira has three primary commercialized products: EXPAREL® (bupivacaine liposome injectable suspension), ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), and ioveraº®. EXPAREL, launched in 2012, is a long-acting local analgesic used for postsurgical pain management, offering significant reductions in opioid consumption and cumulative pain scores. ZILRETTA, approved in 2017, is an extended-release intra-articular injection aimed at managing osteoarthritis knee pain, providing extended pain relief without repeated administration. ioveraº is a novel handheld device that delivers precise, controlled doses of cold temperature to targeted nerves, offering immediate, drug-free pain relief.
The company’s advanced DepoFoam® delivery platform encapsulates drugs in a multivesicular liposome, releasing them over extended periods without altering their molecular structure. This technology underpins the efficacy of Pacira’s flagship product, EXPAREL, which has been pivotal in reducing opioid use and enhancing postoperative recovery.
Pacira continues to innovate with ongoing clinical developments and strategic initiatives. Recently, the company reported preliminary unaudited total revenue of $675.0 million for the fiscal year 2023. In 2024, Pacira plans to launch EXPAREL for two key lower extremity nerve blocks and anticipates the rollout of the NOPAIN Act in 2025, which will expand patient access to opioid-sparing pain management solutions.
Pacira’s commitment to developing non-opioid treatments is further demonstrated by its recent achievements in securing FDA and European Medicines Agency designations for PCRX-201, a gene therapy product candidate for osteoarthritis. The company’s focus on long-term growth and operational excellence remains steadfast under the leadership of CEO Frank D. Lee.
For more information on Pacira BioSciences and its product offerings, visit www.pacira.com.
ImmuneID, Inc. has appointed
Pacira BioSciences, Inc. (Nasdaq: PCRX) announced the publication of full results from its Phase 3 PLAY study of EXPAREL in the Journal of Clinical Anesthesia. The study involved 98 pediatric patients undergoing spinal or cardiac surgeries and demonstrated a favorable safety and pharmacokinetic profile, comparable to traditional bupivacaine. Key findings include no serious adverse events and well-tolerated dosing in all age groups. The results support the FDA approval of EXPAREL for pediatric patients aged 6 and older, reinforcing its role as a non-opioid pain management solution.
Pacira BioSciences (Nasdaq: PCRX) reported a 15% increase in EXPAREL net product sales, totaling $41.4 million for August 2021, up from $36.1 million in the previous year. The utilization of EXPAREL, which has treated over nine million patients, is growing despite challenges in the elective surgery market due to the pandemic. The company maintains a positive outlook, expecting annual growth in the high teens and operating margins exceeding 50%. They continue to provide monthly sales updates amid ongoing uncertainties related to COVID-19.
Pacira BioSciences, Inc. (NASDAQ: PCRX) is set to participate in the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 AM ET. The presentation will be virtual, and investors can access the pre-recorded audio via the company's website. Pacira is recognized for its leadership in non-opioid pain management, particularly through its long-acting local analgesic, EXPAREL®, which launched in April 2012. The company also acquired the iovera°® system in 2019 to enhance its offerings in regenerative health solutions.
Pacira BioSciences reported preliminary net product sales for July 2021, achieving $40.9 million for EXPAREL and $1.0 million for iovera°. Additionally, EXPAREL's average daily sales were 117% of July 2020 levels. This growth is attributed to increasing adoption as a non-opioid analgesic during outpatient surgeries. The company acknowledges ongoing uncertainty in the elective surgery market due to potential COVID-19 variants. Monthly unaudited sales reporting will continue until clearer market visibility is established.
PARSIPPANY, N.J., Aug. 4, 2021 - Pacira BioSciences (NASDAQ: PCRX) will present at the 2021 Wedbush PacGrow Healthcare Virtual Conference on August 10, 2021, at 10:20 AM ET. Interested parties can access the live audio via the company’s website. A replay will be available for two weeks post-event. Pacira is dedicated to non-opioid pain management and regenerative health solutions, highlighted by its long-acting analgesic, EXPAREL, launched in April 2012, and the acquisition of the iovera° system in April 2019.
Pacira BioSciences (PCRX) reported strong second quarter 2021 financial results with total revenues of $135.6 million, up from $75.5 million year-over-year. EXPAREL net sales reached $130.1 million, significantly higher than $73.0 million in Q2 2020. The company achieved a GAAP net income of $19.1 million (or $0.43 per share), a recovery from a loss in the same quarter last year. Adjusted EBITDA soared to $50.3 million. Pacira also announced FDA approval for an enhanced EXPAREL manufacturing process and a distribution agreement with Eurofarma for Latin America, indicating positive growth prospects.
Pacira BioSciences has received FDA approval for an enhanced manufacturing process for its product EXPAREL (bupivacaine liposome injectable suspension), allowing it to double production capacity at a new 200-liter facility in Swindon, England. This move is anticipated to enhance gross margins and extend market exclusivity to January 2041 with the issuance of a new patent. The company aims to commence commercial sales of EXPAREL produced in this facility by the end of the year.
Pacira BioSciences (Nasdaq: PCRX) reported significant findings on the iovera° system from a study focused on total knee arthroplasty (TKA). The addition of preoperative iovera° treatment to a multimodal pain management protocol led to a remarkable 51% reduction in daily opioid consumption and notably decreased pain levels and hospital stay lengths. Analysis of 267 patients showed less than 17% had a hospital stay of two or more days compared to 99% in the control group. These outcomes highlight iovera°'s efficacy in enhancing post-surgical recovery.
Pacira BioSciences, Inc. (NASDAQ:PCRX) will announce its second quarter financial results on August 3, 2021, before U.S. market opening. Following the earnings release, a live conference call will occur at 8:30 a.m. ET. Participants can join the call by dialing 1-877-845-0779 (domestic) or 1-720-545-0035 (international), using passcode 9991311. A replay will be available for one week post-call. Pacira is known for its commitment to non-opioid pain management, with flagship product EXPAREL® launched in 2012, and acquisition of iovera°® system in 2019.
FAQ
What is the current stock price of Pacira Biosciences (PCRX)?
What is the market cap of Pacira Biosciences (PCRX)?
What is Pacira BioSciences, Inc. known for?
What are Pacira BioSciences' main products?
What is EXPAREL used for?
What recent financial milestone did Pacira achieve?
What is ZILRETTA?
How does ioveraº work?
What is the DepoFoam® delivery platform?
What are Pacira’s plans for 2024?
What is PCRX-201?
Where can I learn more about Pacira BioSciences?
